Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1183/09031936.00090614 http://scihub22266oqcxt.onion/10.1183/09031936.00090614 25614164!ä!25614164 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25614164.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Eur+Respir+J 2015 ; 45 (5): 1303-13 Nephropedia Template TP {{tp|p=25614164|t=2015. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) |pdf=|usr=}}{{25614164}} gab.com Text Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) JO: Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=25614164 #FOAvip Riociguat is a soluble, guanylate cyclase stimulator, approved for pulmonary arterial hypertension. In the 12-week PATENT-1 study, riociguat was well tolerated and improved several clinically relevant end-points in patients with pulmonary arterial hypertension who were treatment naive or had been pretreated with endothelin-receptor antagonists or prostanoids. The PATENT-2 open-label extension evaluated the long-term safety and efficacy of riociguat. Eligible patients from the PATENT-1 study received riociguat individually adjusted up to a maximum dose of 2.5 mg three times daily. The primary objective was to assess the safety and tolerability of riociguat; exploratory efficacy assessments included 6-min walking distance and World Health Organization (WHO) functional class. Overall, 396 patients entered the PATENT-2 study and 324 (82%) were ongoing at this interim analysis (March 2013). The safety profile of riociguat in PATENT-2 was similar to that observed in PATENT-1, with cases of haemoptysis and pulmonary haemorrhage also being observed in PATENT-2. Improvements in the patients', 6-min walking distance and WHO functional class observed in PATENT-1 persisted for up to 1 year in PATENT-2. In the observed population at the 1-year time point, mean+/-sd 6-min walking distance had changed by 51+/-74 m and WHO functional class had improved in 33%, stabilised in 61% and worsened in 6% of the patients versus the PATENT-1 baseline. Long-term riociguat was well tolerated in patients with pulmonary arterial hypertension, and led to sustained improvements in exercise capacity and functional capacity for up to 1 year. Twit Text FOAVip Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) ????Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=25614164 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25614164 #FOAvip English Wikipedia <ref>{{Cite pmid|25614164}}</ref> Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) #MMPMID25614164 Rubin LJ; Galie N; Grimminger F; Grunig E; Humbert M; Jing ZC; Keogh A; Langleben D; Fritsch A; Menezes F; Davie N; Ghofrani HA Eur Respir J 2015[May]; 45 (5): 1303-13 PMID25614164show ga Riociguat is a soluble, guanylate cyclase stimulator, approved for pulmonary arterial hypertension. In the 12-week PATENT-1 study, riociguat was well tolerated and improved several clinically relevant end-points in patients with pulmonary arterial hypertension who were treatment naive or had been pretreated with endothelin-receptor antagonists or prostanoids. The PATENT-2 open-label extension evaluated the long-term safety and efficacy of riociguat. Eligible patients from the PATENT-1 study received riociguat individually adjusted up to a maximum dose of 2.5 mg three times daily. The primary objective was to assess the safety and tolerability of riociguat; exploratory efficacy assessments included 6-min walking distance and World Health Organization (WHO) functional class. Overall, 396 patients entered the PATENT-2 study and 324 (82%) were ongoing at this interim analysis (March 2013). The safety profile of riociguat in PATENT-2 was similar to that observed in PATENT-1, with cases of haemoptysis and pulmonary haemorrhage also being observed in PATENT-2. Improvements in the patients', 6-min walking distance and WHO functional class observed in PATENT-1 persisted for up to 1 year in PATENT-2. In the observed population at the 1-year time point, mean+/-sd 6-min walking distance had changed by 51+/-74 m and WHO functional class had improved in 33%, stabilised in 61% and worsened in 6% of the patients versus the PATENT-1 baseline. Long-term riociguat was well tolerated in patients with pulmonary arterial hypertension, and led to sustained improvements in exercise capacity and functional capacity for up to 1 year. |Adult[MESH] |Aged[MESH] |Antihypertensive Agents/therapeutic use[MESH] |Double-Blind Method[MESH] |Endothelin Receptor Antagonists/therapeutic use[MESH] |Exercise Test[MESH] |Female[MESH] |Follow-Up Studies[MESH] |Guanylate Cyclase/metabolism[MESH] |Humans[MESH] |Hypertension, Pulmonary/*drug therapy[MESH] |Kaplan-Meier Estimate[MESH] |Male[MESH] |Middle Aged[MESH] |Patient Safety[MESH] |Prostaglandins/chemistry[MESH] |Pyrazoles/*therapeutic use[MESH] |Pyrimidines/*therapeutic use[MESH] |Quality of Life[MESH] |Time Factors[MESH]Riociguat for the treatment of pulmonary arterial hypertension: a long(epmc).pdf DeepDyve Pubget Overpricing